Skip to main content
Premium Trial:

Request an Annual Quote

Per Petersen, Heino von Prondzynski, Bruce L.A. Carter, David Barker, Warwick Bedwell, Lloyd Miller, Howard Birndorf, David Ludvigson, William Respess, Robert Saltmarsh, Graham Lidgard, Nicholas Kefalides

Premium
Per Petersen has been appointed to Invitrogen’s board of directors after retiring from his post at the chairman of R&D at Johnson & Johnson, the company said last week.
At J&J, Peterson was responsible for the Office of Science and Technology, the R&D Council, and the cell therapy research and activities. Prior to that, Peterson was chairman of the Department of Immunology at the Scripps Research Institute.
 

 
Epigenomics has proposed electing former Roche Diagnostics CEO Heino von Prondzynski to its supervisory board. The vote would take place during Epigenomics’ next annual general meeting of shareholders. The company made the decision during a March 1 meeting of its supervisory board.
 
If elected, von Prondzynski would replace Zymogenetics CEO Bruce L.A. Carter.
Von Prondzynski, who said he has been familiar with Epigenomics since 2002 when the company and Roche became partners, has “been convinced that their DNA methylation approach to molecular diagnostics is unique and bound to become an integral part of early cancer diagnosis and prognosis."
 

 
NextBio this week said it has appointed to its board former Illumina CSO David Barker.
 
NextBio has created a search engine and content knowledgebase that “seamlessly integrates heterogeneous data from all life science sources, changing the way researchers and clinicians work," Barker said in a statement.
 

 
Roche has named Warwick Bedwell vice president and global head of business development of pharma partnering, the company said last week.
 
Bedwell was formerly general manager for Roche Philippines, and was involved in sales and marketing in Australia. He also worked with Schering-Plough in Australia and in Asia.


 
Gene Logic has named investment adviser Lloyd Miller to its board of directors. Miller now “may be deemed to beneficially own” 4.5 million shares in the company, or 14.3 percent of its outstanding shares.
 
With the election to the board, Miller was given a grant of options to buy 30,000 shares of common stock at $1.91 a share, which would be exercisable in four installments beginning in Feb. 2008.
 

 
Nanogen last week reported it has signed a new contract with chairman and CEO Howard Birndorf for a three-year, $520,000 deal that offers potential bonuses that may be as much as 80 percent of his base salary. 
 
The company also has signed new contracts with officers David Ludvigson, William Respess, Robert Saltmarsh, and Graham Lidgard: Ludvigson will receive a base salary of $360,000 with a $180,000 bonus potential; Lidgard will receive $290,000 with a $116,000 bonus potential; Respass will receive $329,000 with a $130,000 bonus potential; and Saltmarsh will receive $257,000 with a $103,000 bonus potential.
 

 
SensiGen this week said Nicholas Kefalides has joined its scientific advisory board. 

Kefalides holds a Bachelor’s degree from Augustana College in Rock Island, Ill., and an MD degree from the University of Illinois College of Medicine

He said SensiGen’s AttoSense technology is a “major breakthrough” in detecting viruses and gene products that signal early onset of disease, and that he is “particularly interested in the application of this new technology on the early detection of kidney disease.”

Filed under